Physalin A (40-80 mg/kg; Intraperitoneal injection; 10 days) has antitumor effect in H292 xenograft tumor model[3].
Physalin A (2 μL 20 μM; Injection of nucleus pulposus of the disc; Single dose) has a protective effect in a rat model of disc degeneration[4].
| Animal Model: | Male BALB/c mice[3] |
| Dosage: | 40 and 80 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); 10 days |
| Result: | Significantly reduced the mean tumor volume and tumor weight, had the least effect on the weight of mice.
Decreased Tyr705-p-STAT3 levels, and increased caspase-3 activation.
|
| Animal Model: | Male Sprague-Dawley rats aged 6-8 weeks old (220±20 g) with intervertebral disc degeneration[4] |
| Dosage: | 2 μL 20 μM |
| Administration: | Injection of nucleus pulposus of the disc; Single dose |
| Result: | Alleviated disc degradation.
Reduced inflammation and fibrosis.
|
